



Versa HD



ELEKTA

Tomas Puusepp

CEO and President, Elekta AB

Dee Mathieson

Senior Vice President, Oncology
Business Line Management

Versa **HD**[™]

Introducing Versa HD

Versa HD is not available for sale or distribution in all markets.
Please contact your Elekta representative for details.



Double the number of patients to be treated




Aspiration
2 million
patients

Today: close to
1 million
patients

- The pioneer of modern cancer care since 1972
- One of the fastest growing companies in the industry
- IGRT 2005, Perfexion™ 2006, VMAT 2008, Agility™ 2012, etc.
- Last year close to 1,000,000 patients benefited from treatment with radiation therapy equipment from Elekta

Increasing population with cancer


1. Number of new cancer cases



- World population growth to 2030: +20%
- Population over 60 years growth: +82%

2. Increasing population living with cancer

- Improved treatments - cancer becomes more of a chronic disease
- Re-treatments



Well positioned for further growth

Versa HD™

1. Enables higher dose per session – delivered more than **three times faster** than before.
2. Minimizes dose to healthy tissue. MLC leaf speeds more than **twice as fast** as other systems.
3. New generation of **patient specific treatments**


Versa HD is a key in Elekta's growth strategy and aspiration to double the number of patients treated with Elekta solutions. Versa HD is CE-marked and elements are pending 510(k) clearance.

Market dynamics




- Linac-based SRS/SRT systems is expected to be the fastest growing segment on the market
- Over 85% of that market will require a highly versatile system capable of a wide spectrum of therapies

Versatility



Conventional
radiotherapy

+



Advanced
stereotactic precision

=



Versa HD
One Solution.
Unlimited Possibilities.

Innovation through collaboration

Translating clinical research into patient benefits

- Elekta Lung Research Group
- Evaluating clinical outcomes in early stage inoperable non-small cell lung cancer

- *Accumulated data for over 800 patients*
- *Identified medical and technical factors that affect tumor control and toxicity*




Beaumont[®]




Versa HD lung treatment

Treatment Planning



Accurate dose calculation

4D Image Guidance



Optimized Dose Placement

Gating



Reduce intra-fraction motion

Advanced Treatment Delivery



High-resolution MLC with High Dose Rates





Protect Critical Structures

MOSAIQ OIS

Delivering 'Evidence based Medicine'

Versa HD lung treatment



High Dose Rate mode

- Improve treatment times with escalated SRS/SRT dose regimens

Lung	Previous Generation	Versa HD
PTV prescription	60 Gy	60 Gy
Number of fractions	5	5
Dose per fraction	12 Gy	12 Gy
Beam-on time per fraction	3 mins 50 seconds	2 mins 10 seconds

49% faster

Enhanced patient and clinician experience

Confident and relaxed treatment environment

Fewer delays and reduced downtime

- 30% less power consumption
- Lower operating temperature
- Reduced cost of operation



Well positioned for further growth

Versa HD™

1. Enables higher dose per session – delivered more than **three times faster** than before.
2. Minimizes dose to healthy tissue. MLC leaf speeds more than **twice as fast** as other systems.
3. New generation of **patient specific treatments**

Versa HD is a key in Elekta's growth strategy and aspiration to double the number of patients treated with Elekta solutions. Versa HD is CE-marked and elements are pending 510(k) clearance.

Versa **HD**[™]

Q&A

Versa HD is not available for sale or distribution in all markets.
Please contact your Elekta representative for details.



VersaHD



ELEKTA

www.VersaHD.com